{
  "slug": "eli-lilly-and-company",
  "symbol": "LLY",
  "name": "Eli Lilly and Company",
  "fiscalYearEnd": "2025-12-31",
  "filing": {
    "accession": "0000059478-26-000013",
    "form": "10-K",
    "filed": "2026-02-12",
    "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947826000013/lly-20251231.htm"
  },
  "model": "claude-haiku-5-5",
  "promptVersion": "2026-10-31.2",
  "generatedAt": "2026-10-31T19:39:08.533780+00:00",
  "segments": null,
  "sections": {
    "businessModel": [
      {
        "de": "Das Unternehmen entdeckt, entwickelt, stellt her und vermarktet Produkte in einem Geschäftssegment.",
        "en": "The company discovers, develops, manufactures and markets products in one business segment.",
        "quote": "We discover, develop, manufacture, and market products in a single business segment"
      },
      {
        "de": "In bestimmten Rechtsordnungen liefert LillyDirect, eine digitale Gesundheitsplattform für den direkten Weg zu Patienten, ausgewählte Lilly-Medikamente, die Drittapotheken an Patienten abgeben.",
        "en": "In certain jurisdictions, LillyDirect, a direct-to-patient digital health care platform, delivers select Lilly medicines that third-party pharmacies dispense to patients.",
        "quote": "In certain jurisdictions, we utilize LillyDirect, our direct-to-patient digital health care platform, to provide delivery of select Lilly medicines dispensed by third-party pharmacies to patients."
      },
      {
        "de": "Anti-Adipositas-Medikamente machen einen erheblichen Teil der Umsätze des Unternehmens aus.",
        "en": "Anti-obesity medicines make up a significant portion of the company's revenues.",
        "quote": "Our anti-obesity medicines comprise a significant portion of our revenues"
      },
      {
        "de": "Die Produkte des Unternehmens werden in etwa 90 Ländern verkauft.",
        "en": "The company's products are sold in approximately 90 countries.",
        "quote": "Our products are sold in approximately 90 countries."
      }
    ],
    "customers": [
      {
        "de": "Kundenbetreuer bedienen Großhändler, Pharmacy Benefit Manager, Versicherer, Arbeitgeber, Krankenhäuser und bestimmte Einzelhandelsapotheken.",
        "en": "Account managers serve wholesalers, pharmacy benefit managers, insurers, employers, hospitals and certain retail pharmacies.",
        "quote": "Our account managers service wholesalers, pharmacy benefit managers, insurers, plan sponsors, employers, managed care organizations, group purchasing organizations, government and long-term care institutions, hospitals, and certain retail pharmacies."
      },
      {
        "de": "Selbstzahlende Patienten kaufen über LillyDirect, und diese Verkäufe machten 2025 einen wachsenden Teil des Geschäfts aus.",
        "en": "Patients who pay themselves buy through LillyDirect, and these sales made up a growing part of the business in 2025.",
        "quote": "In addition, patient self-pay sales through LillyDirect represented a growing portion of our business in 2025"
      }
    ],
    "competition": [
      {
        "de": "Die Produkte des Unternehmens konkurrieren weltweit mit vielen anderen Arzneimitteln in sehr wettbewerbsintensiven Märkten.",
        "en": "The company's products compete worldwide with many other pharmaceutical products in highly competitive markets.",
        "quote": "Our products compete globally with many other pharmaceutical products in highly competitive markets."
      },
      {
        "de": "Wichtige Wettbewerbsfaktoren sind Wirksamkeit, Sicherheit, Verfügbarkeit, einfache Anwendung, Patientenpräferenz, Preis sowie Kostenübernahme und Erstattungssätze durch Kostenträger.",
        "en": "Important factors in competition include effectiveness, safety, availability, ease of use, patient preference, price, and payer coverage and reimbursement rates.",
        "quote": "Important competitive factors include effectiveness, safety, availability, ease of use, patient preference, and overall experience; formulary placement, price, payer coverage and reimbursement rates, and demonstrated cost-effectiveness"
      },
      {
        "de": "Generika und Biosimilars können für das Geschäft des Unternehmens erhebliche Wettbewerbsherausforderungen darstellen.",
        "en": "Generic medicines and biosimilars can pose major competitive challenges to the company's business.",
        "quote": "Generic pharmaceuticals and biosimilars can pose major competitive challenges to our business."
      }
    ],
    "risks": [
      {
        "de": "Für Trulicity laufen in den nächsten Jahren erheblicher Patentschutz und verbleibende Datenexklusivität aus.",
        "en": "Trulicity will lose significant patent and remaining data protection in the next few years.",
        "quote": "For example, Trulicity will lose significant patent and remaining data protections in the next few years."
      },
      {
        "de": "Mounjaro und Zepbound machten 2025 56 Prozent des Gesamtumsatzes des Unternehmens aus.",
        "en": "Mounjaro and Zepbound accounted for 56 percent of the company's total revenues in 2025.",
        "quote": "In particular, Mounjaro and Zepbound accounted for 56 percent of our total revenues in 2025"
      },
      {
        "de": "Im August 2023 wählte HHS Jardiance für staatlich festgelegte Preise in Medicare aus, die ab 2026 gelten, mit einem erheblichen Abschlag.",
        "en": "In August 2023, HHS selected Jardiance for government-set prices in Medicare, effective from 2026, at a significant discount.",
        "quote": "In August 2023, HHS selected Jardiance, which is part of our collaboration with Boehringer Ingelheim, as one of the first ten medicines subject to government-set prices in Medicare (effective beginning in 2026) at a significant discount"
      },
      {
        "de": "Änderungen am 340B-Programm oder an den Medicaid-Programmen könnten wesentliche nachteilige Auswirkungen auf das Geschäft haben.",
        "en": "Changes to the 340B program or the Medicaid programs could have a material adverse impact on the business.",
        "quote": "Changes to the 340B program or the Medicaid programs could have a material adverse impact on our business."
      },
      {
        "de": "Das Unternehmen beobachtet weiterhin, dass gefälschte, falsch gekennzeichnete, verunreinigte und massenhaft nachgemischte Inkretin-Arzneimittel in den USA und anderen Märkten verkauft werden.",
        "en": "The company continues to see counterfeit, misbranded, adulterated and mass-compounded incretin drugs sold in the U.S. and other markets.",
        "quote": "We continue to see the production, marketing, and sale of counterfeit, misbranded, adulterated, and mass-compounded incretins in the U.S. and other markets."
      }
    ]
  }
}